{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:22:20Z","timestamp":1794018140775,"version":"4.8.0"},"reference-count":136,"publisher":"Korean Diabetes Association","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["e-dmj.org"],"crossmark-restriction":true},"short-container-title":["Diabetes Metab J"],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:p>Diabetic kidney disease (DKD) is a leading cause of end-stage kidney disease and significantly increases cardiovascular risk and mortality. Despite conventional therapies, including renin-angiotensin-aldosterone system inhibitors, substantial residual risk remains. The emergence of sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists has reshaped DKD management. Beyond glycemic control, these agents provide distinct and complementary cardiorenal benefits through mechanisms such as hemodynamic modulation, anti-inflammatory effects, and metabolic adaptations. Landmark trials, including CREDENCE, DAPA-CKD, EMPA-KIDNEY, and FLOW, have demonstrated their efficacy in preserving kidney function and reducing adverse outcomes. SGLT2 inhibitors appear more effective in mitigating glomerular hyperfiltration and lowering heart failure risk, whereas GLP-1 receptor agonists are particularly beneficial in reducing albuminuria and atherosclerotic cardiovascular events. Although indirect comparisons suggest that SGLT2 inhibitors may offer greater protection against kidney function decline, direct head-to-head trials are lacking. Combination therapy holds promise, however further studies are needed to define optimal treatment strategies. This review synthesizes current evidence, evaluates comparative effectiveness, and outlines future directions in DKD management, emphasizing precision medicine approaches to enhance clinical outcomes. The integration of these therapies represents a paradigm shift in diabetes care, expanding treatment options for people with diabetes mellitus at risk of kidney failure.<\/jats:p>","DOI":"10.4093\/dmj.2025.0220","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T01:32:56Z","timestamp":1746149576000},"page":"386-402","update-policy":"https:\/\/doi.org\/10.4093\/crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application"],"prefix":"10.4093","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1384-6123","authenticated-orcid":true,"given":"Jae Hyun","family":"Bae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2567","reference":[{"key":"ref1","first-page":"15018","volume-title":"Diabetic kidney disease","author":"Thomas","year":"2015"},{"key":"ref2","first-page":"709","volume-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","year":"2020"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2023.0310"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvad083"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.120.050686"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0175"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199311113292004"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa011303"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-021-00522-3"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.00840207"},{"key":"ref11","first-page":"2019","volume-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","author":"Pfeffer","year":"2009"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2009060593"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1208799"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1306033"},{"key":"ref15","first-page":"414","volume-title":"Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial","author":"Mann","year":"2013"},{"key":"ref16","first-page":"1937","volume-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","author":"Heerspink","year":"2019"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-022-00535-6"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2017.123"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2337\/dci23-0030"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-024-00827-z"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.08.010"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfw070"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.49.11.1939"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/414813a"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-021-00393-8"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4654-7"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.116.021887"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4669-0"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1172\/jci164486"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1172\/jci167700"},{"key":"ref31","first-page":"169","volume-title":"SGLT2 inhibitor-induced sympathoinhibition: a novel mechanism for cardiorenal protection","author":"Herat","year":"2020"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-019-1165-1"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.02.020"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-020-00350-x"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.122.061732"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1504720"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1611925"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1812389"},{"key":"ref39","first-page":"1433","volume-title":"Empagliflozin and cardiovascular and kidney outcomes across KDIGO risk categories: post hoc analysis of a randomized, double-blind, placebo-controlled, multinational trial","author":"Levin","year":"2020"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(18)30141-4"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.118.035901"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2019010064"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2020.06.018"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(19)30180-9"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.4511"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1811744"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2024816"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2204233"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-1450"},{"key":"ref50","first-page":"3724","volume-title":"The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: insights from the CANVAS program and CREDENCE trial","author":"Yu","year":"2023"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(20)30162-5"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-0300"},{"key":"ref53","first-page":"51","volume-title":"Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPAKIDNEY trial","year":"2024"},{"key":"ref54","first-page":"39","volume-title":"Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the EMPA-kidney trial","year":"2024"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(21)00243-6"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2021020167"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05694-6"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(21)00242-4"},{"key":"ref59","first-page":"1788","volume-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","year":"2022"},{"key":"ref60","first-page":"384","volume-title":"Kidney, cardiovascular, and safety outcomes of canagliflozin according to baseline albuminuria: a CREDENCE secondary analysis","author":"Jardine","year":"2021"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnaa032"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-022-00783-3"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1371"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12808"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12985"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1958"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.121.055459"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14443"},{"key":"ref70","first-page":"131","volume-title":"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial","author":"Gerstein","year":"2019"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2108269"},{"key":"ref72","first-page":"565","volume-title":"Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose cotransporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O trial","author":"Lam","year":"2022"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(21)00203-5"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad009"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2403347"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03133-0"},{"key":"ref77","first-page":"m4573","volume-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network metaanalysis of randomised controlled trials","author":"Palmer","year":"2021"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01197-z"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109146"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.06.016"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-1890"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06251-z"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000001184"},{"key":"ref84","first-page":"S181","volume-title":"9","year":"2025"},{"key":"ref85","first-page":"575","volume-title":"2023 Clinical practice guidelines for diabetes mellitus of the Korean Diabetes Association","author":"Choi","year":"2023"},{"key":"ref86","first-page":"4043","volume-title":"2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes","author":"Marx","year":"2023"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.119.044235"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(20)30300-4"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab497"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.121.057736"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02463-0"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-024-00997-0"},{"key":"ref93","first-page":"1394","volume-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","author":"Kosiborod","year":"2024"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(24)00304-8"},{"key":"ref95","first-page":"27","volume-title":"Semaglutide and NT-proBNP in obesity-related HFpEF: insights from the STEP-HFpEF program","author":"Petrie","year":"2024"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.08.021"},{"key":"ref97","first-page":"1646","volume-title":"Inflammation in obesity-related HFpEF: the STEPHFpEF program","author":"Verma","year":"2024"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.031"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2024.0541"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(21)00020-0"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-332687"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.14336"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab274"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2021.0356"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4147"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2024.0036"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-0946"},{"key":"ref108","first-page":"1345","volume-title":"Ertugliflozin and slope of chronic eGFR: prespecified analyses from the randomized VERTIS CV trial","author":"Cherney","year":"2021"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06126-3"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.50050"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.03.390"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.2337\/dci24-0003"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(20)30313-2"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae613"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.57349"},{"key":"ref116","first-page":"1414","volume-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","author":"Rubino","year":"2021"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2409183"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(24)00155-4"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.124.071689"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(16)30267-4"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(19)30066-x"},{"key":"ref122","first-page":"1851","volume-title":"Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: a prespecified secondary analysis of a randomized controlled clinical trial","author":"van Ruiten","year":"2021"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15033"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-05876-w"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2022.05.010"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.09.029"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.7326\/m23-1492"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(21)00240-0"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2025845"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2110956"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab777"},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03264-4"},{"key":"ref133","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad522"},{"key":"ref134","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-0671"},{"key":"ref135","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.27402"},{"key":"ref136","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)02617-5"}],"container-title":["Diabetes &amp; Metabolism Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-dmj.org\/upload\/pdf\/dmj-2025-0220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-dmj.org\/journal\/view.php?doi=10.4093\/dmj.2025.0220","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-dmj.org\/upload\/pdf\/dmj-2025-0220.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T02:17:29Z","timestamp":1747189049000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-dmj.org\/journal\/view.php?doi=10.4093\/dmj.2025.0220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":136,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"URL":"https:\/\/doi.org\/10.4093\/dmj.2025.0220","relation":{},"ISSN":["2233-6079","2233-6087"],"issn-type":[{"value":"2233-6079","type":"print"},{"value":"2233-6087","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,1]]},"assertion":[{"value":"2025-03-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-01","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-01","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}